Company intelligence / Profile preview

Pear Therapeutics

Boston, Massachusetts, United Statesdtxalliance.org ↗

Ownership: Private
Employees: ~77
Development stage: Commercial

Overview

Pear was the first company to receive FDA authorization for a prescription digital therapeutic with reSET® for SUD. It subsequently received authorizations for reSET-O® for OUD and Somryst® for chronic insomnia. Clinical results demonstrated efficacy in delivering evidence-based cognitive behavioral therapy through software applications as adjuncts or alternatives to traditional pharmacotherapy. Other pipeline programs targeted psychiatric and neurological disorders but did not reach commercialization before bankruptcy.

Therapeutic areas: PsychiatryNeurology
Modalities: Non-pharmacological therapy (Prescription Digital Therapeutics)Device (Software as a Medical Device)Behavioral therapy (delivered digitally)Cognitive behavioral therapy (delivered digitally)
Industry: Digital Health Medical Devices

Drug pipeline

3 assets

reSET

Commercial

Indications: Substance use disorder

2 more assets in the full pipeline.

Request access →

Partnerships

Novartis/Sandoz

Beyond the preview

Go deeper on Pear Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Pear Therapeutics.

Explore the full profile